Therapeutic agent

Metformin

Also known as: Metformin

ModerateEvidence level
3Registered trials
3Conditions
1Study references

Evidence Summary

Evidence Level
Moderate
Mechanism
Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Metabolic / Mitochondrial
Safety
GI side effects (diarrhea, nausea) common initially. Risk of B12 deficiency long-term; lactic acidosis rare (avoid in severe renal/hepatic disease, contrast).
Dosing
500–2000 mg/day (extended release often better tolerated); prevention trials used during acute infection ~14 days; treatment studies 8–12+ weeks.
Prevention signal strong; treatment data mixed/preliminary. 500-2000mg. GI effects, B12. Reasonable metabolic adjunct in overweight PASC patients.

Clinical Trials

3 trial(s) registered

NCT IDTitlePhaseStatus
NCT04510194COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)Phase 3Completed
NCT06128967A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE TrialPhase 3Completed
NCT06147050Effect of Metformin in Reducing Fatigue in Long COVID in AdolescentsPhase 3Unknown status

Key Studies / References